Clinical trial
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in…
NCT00146549 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00146549 |
|---|---|
| Title | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer |
| Official title | A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Brigham and Women's Hospital North Shore Medical Center GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab, Vinorelbine, Paclitaxel, Docetaxel |
| Enrollment | 250 |
| Start date | Aug 1, 2001 |
| Primary completion | Aug 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Nov 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: